Torsades de Pointes during Treatment of Tachycardia-Induced Cardiomyopathy
´ëÇÑÁßȯÀÚÀÇÇÐȸÁö 2014³â 29±Ç 1È£ p.19 ~ p.22
À̵¿±Ô(Lee Dong-Kyu) - Eulji University Hospital Department of Internal Medicine
À¯ÀÏȯ(Ryu Il-Hwan) - Eulji University Hospital Department of Internal Medicine
À¯ÁöÇü(Yoo Ji-Hyung) - Eulji University Hospital Department of Internal Medicine
(Yun Su-A) - Eulji University Hospital Department of Internal Medicine
¹Ú»óÇö(Park Sang-Hyun) - Eulji University Hospital Department of Internal Medicine
°±â¿î(Kang Ki-Woon) - Eulji University Hospital Department of Internal Medicine
±è¿øÈ£(Kim Won-Ho) - Eulji University Hospital Department of Internal Medicine
ÃÖÀ¯Á¤(Choi Yu-Jeong) - Eulji University Hospital Department of Internal Medicine
Á¤°æÅÂ(Jung Kyung-Tae) - Eulji University Hospital Department of Internal Medicine
ÁøÁ¤¿¬(Chin Jung-Yeon) - Eulji University Hospital Department of Internal Medicine
Abstract
Tachycardia-induced cardiomyopathy is caused by persistent tarchyarrhythmias and is characterized by ventricular systolic dysfunction and congestive heart failure. Tachycardia-induced cardiomyopathy is usually reversible via treatment. The cornerstone in the management of disease in these patients is to achieve a normal heart rate. We report a torsades de pointes during treatment of tachycardia-induced cardiomyopathy. Intravenous magnesium sulfate and potassium were administrated, but torsades de pointes was repeated. After overdrive right ventricular pacing, torsades de pointes was terminated. Careful monitoring of the QT interval and serum electrolyte and drug levels in such patients is warranted during treatment of tachycardia-induced cardiomyopathy.
Å°¿öµå
cardiomyopathies, tachycardia, torsades de pointes
KMID :
0604020140290010019
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)